Fig 1: Overexpression of activating transcription factor 4 (ATF4) or CAAT/enhancer binding protein‐α homologous protein (CHOP) increased resistin messenger ribonucleic acid (mRNA) in THP‐1 human monocytes. THP‐1 cells were transfected with each of 20 μg of plasmid deoxyribonucleic acid, pCMV6‐XL5 containing the coding sequence of human ATF4 or pCMV6‐AC containing the coding sequence of human CHOP, and were subsequently incubated in the medium for 48 h. The mRNA of ATF4, CHOP and resistin (RETN) was quantitated using reverse transcription polymerase chain reaction and shown relative to 18S rRNA mRNA as described in the Materials and Methods. The mRNA of the control (empty pCMV6‐XL5 or pCMV6‐AC) is defined as 1.0. The mean ± standard error of the mean of five separate experiments with duplicate samples is shown. Unpaired Student's t‐test was used for statistical analyses. **P < 0.01, *P < 0.05.
Fig 2: ER stress does not induce sustained upregulation of BimEL in melanoma cells. (a) TM induces sustained upregulation of BimEL in MCF-7 breast cancer cells but not in Mel-RM melanoma cells. Left: 30μg of total protein of whole-cell lysates from Mel-RM and MCF-7 cells treated with TM (3 μM) for indicated periods were subjected to western blot analysis of Bim and GAPDH (as a loading control). The arrowhead points to a band of unknown origin generated with the antibody against Bim. Right: quantitative expression levels of BimEL as shown the left panel that were normalized to GAPDH. Quantitation of each band was carried out with ImageReader LAS-4000. The data shown are representative of three individual experiments. (b) TM does not induce sustained upregulation of BimEL in IgR3, Sk-Mel-28, and MM200 melanoma cells. Thirty microgram of total protein of whole-cell lysates from IgR3, Sk-Mel-28, and MM200 treated with TM (3 μM) for indicated periods were subjected to western blot analysis of Bim and GAPDH (as a loading control). The arrowhead points to a band of unknown origin generated with the antibody against Bim. The data shown are representative of three individual experiments. (c) Melanoma cells are not sensitive to ER stress-induced apoptosis. Mel-RM and MM200 melanoma cells, and MCF-7 breast cancer cells were treated with TM (3 μM) for 48 h before apoptosis was measured by the PI method using flow cytometry. The data shown are the mean±S.E. of three individual experiments. (d) TG does not induce sustained upregulation of BimEL in melanoma cells. Thirty microgram of total protein of whole-cell lysates from Mel-RM and MM200 melanoma cells treated with TG (1 μM) for indicated periods were subjected to western blot analysis of Bim and GAPDH (as a loading control). The data shown are representative of three individual experiments. (e) Induction of ER stress by TM in Mel-RM and MM200 melanoma cells and MCF-7 breast cancer cells. Mel-RM, MM200, and MCF-7 cells were treated with TM (3 μM) for indicated periods. For examining the expression of GRP78 and CHOP, 30 μg of total protein of whole-cell lysates were subjected to western blot analysis of GRP78, CHOP, and GAPDH (as a loading control). The arrowhead points to a non-specific band generated with the antibody against CHOP. For examining activation of XBP1, RT-PCR products of XBP1 mRNA and β-actin mRNA (as a control) from total RNA extracts were digested with ApaLI for 90 min followed by electrophoresis. The longer fragment derived from the active form of XBP1 mRNA and two shorter bands derived from the inactive form are indicated. The data shown are representative of three individual experiments
Fig 3: The 4‐phenylbutyrate (4‐PBA) reduced tunicamaycin‐induced resistin and ER stress markers messenger ribonucleic acid (mRNA) in THP‐1 human monocytes. THP‐1 cells were pre‐incubated with 750, 1,500, 3,000 or 7,500 μmol/L of 4‐PBA, a chemical chaperone, for 14 h, and 0.1 μg/mL tunicamycin was subsequently added to the medium for 24 h. The mRNA of (a) endoplasmic reticulum stress markers (immunoglobulin heavy chain‐binding protein [BiP], pancreatic endoplasmic reticulum eukaryotic initiation factor 2α kinase [PERK], activating transcription factor 4 [ATF4], CAAT/enhancer binding protein‐α homologous protein [CHOP], ATF6, inositol requiring enzyme 1 [IRE1] and X‐box binding protein 1 [XBP1]) and (b) resistin (RETN) were quantitated using reverse transcription polymerase chain reaction and shown relative to 18S rRNA mRNA as described in the Materials and Methods. The mRNA of control (4‐PBA [–], tunicamycin [–]) was defined as 1.0. The mean ± standard error of the mean of five separate experiments with triplicate samples is shown. anova; P = 8.49 × 10−8 (BiP), P = 0.00040 (PERK), P = 2.46 × 10−6 (ATF4), P = 1.53 × 10−5 (CHOP), P = 0.00085 (ATF6), P = 0.0070 (IRE1), P = 0.00016 (XBP1), P = 5.44 × 10−6 (RETN); Scheffe's test; ††P < 0.01, †P < 0.05 vs control (tunicamycin [–], 4‐PBA [–]), **P < 0.01, *P < 0.05.
Fig 4: The knockdown of pancreatic endoplasmic reticulum eukaryotic initiation factor 2α kinase (PERK), activating transcription factor 4 (ATF4) or CAAT/enhancer binding protein‐α homologous protein (CHOP) inhibited tunicamycin‐induced resistin messenger ribonucleic acid (mRNA) in THP‐1 human monocytes. THP‐1 cells were transfected with each of 500 nmol/L small interfering RNA (siRNA), and 0.1 μg/mL tunicamycin was subsequently added to the medium for 24 h. The mRNA of PERK, ATF4, CHOP and resistin (RETN) was quantitated using reverse transcription polymerase chain reaction, and are shown relative to 18S rRNA mRNA as described in the Materials and Methods. The effect of siRNA for (a) PERK, (b) ATF4 and (c) CHOP. The mRNA of control (tunicamycin [–]) is defined as 1.0. The mean ± standard error of the mean of six separate experiments with duplicate samples is shown. anova; (a) P = 1.29 × 10−8 (PERK), P = 3.79 × 10−6 (RETN), (b) P = 4.01 × 10−9 (ATF4), P = 0.0016 (RETN), (c) P = 5.85 × 10−11 (CHOP), P = 2.14 × 10−6 (RETN), Scheffe's test; ††P < 0.01 vs control (tunicamycin [–], siRNA [–]), **P < 0.01, *P < 0.05.
Fig 5: Endoplasmic reticulum stress, induced by tunicamycin, increased resistin messenger ribonucleic acid (mRNA) in THP‐1 human monocytes. (a) Tunicamycin increased resistin mRNA in THP‐1 human monocytes (dose–response). THP‐1 cells were treated with 0 (control), 0.01, 0.1 or 1.0 μg/mL tunicamycin for 24 h. The mRNA of human resistin was quantitated using reverse transcription polymerase chain reaction, and the data are shown relative to 18S rRNA mRNA as described in the Materials and Methods. The mRNA of the control was defined as 1.0. The mean ± standard error of the mean of six separate experiments with triplicate samples is shown. anova and Scheffe's test were used for statistical analyses. anova; P = 0.0014, Scheffe's test; *P < 0.01 compared with control, †P < 0.05 compared with 0.01 μg/mL tunicamycin. (b) (Time‐course) THP‐1 cells were treated with 0.1 μg/mL tunicamycin for 4, 8, 12, 24, 48 or 72 h. The mRNA of the control (0 h) was defined as 1.0. The mean ± standard error of the mean of six separate experiments with triplicate samples are shown. anova; P = 2.63 × 10–6; Scheffe's test; *P < 0.01 compared with 4 and 72 h in THP‐1 cells treated with 0.1 μg/mL tunicamycin, †P < 0.05 compared with 8, 12 and 48 h in THP‐1 cells treated with 0.1 μg/mL tunicamycin. (c) The mRNA of endoplasmic reticulum stress markers, immunoglobulin heavy chain‐binding protein (BiP), pancreatic endoplasmic reticulum eukaryotic initiation factor 2α kinase (PERK), activating transcription factor 4 (ATF4), CAAT/enhancer binding protein‐α homologous protein (CHOP), inositol requiring enzyme 1 (IRE1) or X‐box binding protein 1 (XBP1) was increased by tunicamycin. THP‐1 cells were treated with 0.1 μg/mL tunicamycin for 24 h. The mRNA of control (tunicamycin [–], 24 h) was defined as 1.0. The mean ± standard error of the mean of six separate experiments with triplicate samples is shown. Unpaired Student's t‐test was used for statistical analyses. *P < 0.01, **P < 0.001 vs control.
Supplier Page from OriGene Technologies for DDIT3 (NM_004083) Human Untagged Clone